Stefania Ferrari

Stefania Ferrari

Auto-generated profile, based on publicly available information

Stefania Ferrari

Department of Life Sciences, University of Modena and Reggio Emilia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Matteo SantucciMatteo Santucci
Matteo Santucci
TVTatiana Vignudelli
Tatiana Vignudelli
SFStefania Ferrari
Stefania Ferrari
Marco MorMarco Mor
Marco Mor
LSLaura Scalvini
Laura Scalvini
MCMaria Paola Costi
Maria Paola Costi

9 December 2014 in ACS Chemical Biology
Verified
Journal Article
Closed access
JNJoão Neres
João Neres
RHRuben C Hartkoorn
Ruben C Hartkoorn
Laurent Roberto ChiarelliLaurent Roberto Chiarelli
Laurent Roberto Chiarelli
RGRamakrishna Gadupudi
Ramakrishna Gadupudi
MPMaria Rosalia Pasca
Maria Rosalia Pasca
SCStewart T. Cole
Stewart T. Cole

5 February 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ACAntonio Cavazzuti
Antonio Cavazzuti
GPGiuseppe Paglietti
Giuseppe Paglietti
WHWilliam N. Hunter
William N. Hunter
FGFrancisco Gamarro
Francisco Gamarro
SPSandra Piras
Sandra Piras
MCMaria Paola Costi
Maria Paola Costi
Pteridine reductase (PTR1) is essential for salvage of pterins by parasitic trypanosomatids and is a target for the development of improved therapies. To identify inhibitors of Leishmania major and Trypanosoma cruzi PTR1, we combined a rapid-screening strategy using a folate-based library with structure-based design. Assays were carried out against folate-dependent enzymes including PTR1, dihydrofolate reductase (DHFR), and thymidylate synthase. Affinity profiling determined selectivity and specificity of a series of quinoxaline and 2,4-diaminopteridine derivatives, and nine compounds showed greater activity against parasite enzymes compared with human enzymes. Compound 6a displayed a K i of 100 nM toward Lm PTR1, and the crystal structure of the Lm PTR1:NADPH:6a ternary complex revealed a substrate-like binding mode distinct from that previously observed for similar compounds. A second round of design, synthesis, and assay produced a compound (6b) with a significantly improved K i (37 nM) against Lm PTR1, and the structure of this complex was also determined. Biological evaluation of selected inhibitors was performed against the extracellular forms of T. cruzi and L. major , both wild-type and overexpressing PTR1 lines, as a model for PTR1-driven antifolate drug resistance and the intracellular form of T. cruzi. An additive profile was observed when PTR1 inhibitors were used in combination with known DHFR inhibitors, and a reduction in toxicity of treatment was observed with respect to administration of a DHFR inhibitor alone. The successful combination of antifolates targeting two enzymes indicates high potential for such an approach in the development of previously undescribed antiparasitic drugs.

1 September 2005 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MCMaria Paola Costi
Maria Paola Costi
SFS. Ferrari
S. Ferrari
AVA. Venturelli
A. Venturelli
SCS. Calo
S. Calo
Donatella TondiDonatella Tondi
Donatella Tondi
DBD. Barlocco
D. Barlocco
Recent methodologies applied to the drug discovery process, such as genomics and proteomics, have greatly implemented our basic understanding of drug action and are giving more input to medicinal chemists, in finding genuinely new targets and opportunities for the development of drugs with original mechanisms of action. In this paper, an example of the successful application of some new techniques to the target enzymes with the Thymidylate Synthase (TS) function is given. The improved knowledge of the complex mechanism of the biological pathways in which thymidylate synthase is involved represents a unique chance to find new mechanism-based inhibitors, aimed to treat not only cancerous diseases, but also infectious pathologies. Thymidylate synthase (TS or ThyA) has long been considered as one of the best-known drug targets in the anti-cancer area, after which old and new drugs, such as 5-fluoro uracil and the anti-folate ZD1694, have been introduced into chemotherapy to treat solid tumours. Only a few attempts have been made to find non-classical anti-folate inhibitors that are dissimilar to the folate co-factor, with the aim of finding unshared protein target domains on the enzyme structure, in order to specifically inhibit TS enzymes from pathogens. Only recently from omic studies, a new Thymidylate Synthase Complementing Protein (TSCP or ThyX) has been identified in a number of pathogens, showing a different structure with respect to human TS, thus opening new avenues to specific inhibitions. A depiction of the most recent progress in the study of Thymidylate Synthase enzymes is presented in the following sections.

27 July 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DCDaniela Cardinale
Daniela Cardinale
GGGiambattista Guaitoli
Giambattista Guaitoli
Donatella TondiDonatella Tondi
Donatella Tondi
RLRosaria Luciani
Rosaria Luciani
SHStefan Henrich
Stefan Henrich
MCMaria Paola Costi
Maria Paola Costi
Human thymidylate synthase is a homodimeric enzyme that plays a key role in DNA synthesis and is a target for several clinically important anticancer drugs that bind to its active site. We have designed peptides to specifically target its dimer interface. Here we show through X-ray diffraction, spectroscopic, kinetic, and calorimetric evidence that the peptides do indeed bind at the interface of the dimeric protein and stabilize its di-inactive form. The “LR” peptide binds at a previously unknown binding site and shows a previously undescribed mechanism for the allosteric inhibition of a homodimeric enzyme. It inhibits the intracellular enzyme in ovarian cancer cells and reduces cellular growth at low micromolar concentrations in both cisplatin-sensitive and -resistant cells without causing protein overexpression. This peptide demonstrates the potential of allosteric inhibition of hTS for overcoming platinum drug resistance in ovarian cancer.

2 December 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SFStefania Ferrari
Stefania Ferrari
FMFederica Morandi
Federica Morandi
DMDomantas Motiejunas
Domantas Motiejunas
ENErika Nerini
Erika Nerini
SHStefan Henrich
Stefan Henrich
MCMaria Paola Costi
Maria Paola Costi